Genmab — Marts 2019
-
De vil vel bare have den ned i dag...op på mandag...osv. Det er deres måde at lave penge på.
-
Der bliver længere og længere til 1280..:-(
-
Karyopharm stiger 22% på forlængelse af FDA-review https://seekingalpha.com/pr/17445029-karyopharm-announces-fda-extension-review-period-selinexor-new-drug-application
-
Ja, det er en underlig kursudvikling i Genmab - fortsat. Ville være fint med at afgørende brud væk far kurs 1200 i opadgående retning.
-
Tror jeg også.
-
Tjah..så er vi tilbage til håb og tro!
-
Bud i luk omkring 1115!!
-
Må sige at jeg synes Genmab aktie er meget svag i øjeblikket.
-
Selv med god grøn uge
-
Ang jnj-372 og Lazertinib: Pre-clinical results of the combo of Janssen’s bispecific antibody JNJ-372 (EGFR x cMET) and Lazertinib should be presented at AACR in April https://rreport.einfomax.co.kr/report/ezkleiiezliekezgcemcegz.pdf
-
God morgen til en regnfuld dag.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind